Tower Research Capital LLC TRC raised its position in shares of Diplomat Pharmacy Inc. (NYSE:DPLO) by 12,630.3% during the second quarter, Holdings Channel reports. The institutional investor owned 4,201 shares of the company’s stock after buying an additional 4,168 shares during the period. Tower Research Capital LLC TRC’s holdings in Diplomat Pharmacy were worth $147,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in DPLO. PineBridge Investments L.P. purchased a new position in Diplomat Pharmacy during the second quarter valued at approximately $161,000. Springbok Capital Management LLC boosted its position in Diplomat Pharmacy by 14.8% in the first quarter. Springbok Capital Management LLC now owns 6,664 shares of the company’s stock valued at $183,000 after buying an additional 857 shares during the period. Teacher Retirement System of Texas boosted its position in Diplomat Pharmacy by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,404 shares of the company’s stock valued at $189,000 after buying an additional 655 shares during the period. Menta Capital LLC purchased a new position in Diplomat Pharmacy during the first quarter valued at approximately $200,000. Finally, Telemus Capital LLC purchased a new position in Diplomat Pharmacy during the second quarter valued at approximately $225,000. 75.90% of the stock is owned by institutional investors and hedge funds.
Shares of Diplomat Pharmacy Inc. (NYSE:DPLO) opened at 28.36 on Friday. The company’s 50-day moving average is $30.59 and its 200 day moving average is $32.06. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of 43.63 and a beta of 1.06. Diplomat Pharmacy Inc. has a 1-year low of $22.41 and a 1-year high of $38.94.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Tuesday, August 9th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The company earned $1.09 billion during the quarter, compared to the consensus estimate of $1.12 billion. Diplomat Pharmacy had a net margin of 1.08% and a return on equity of 11.57%. The firm’s revenue for the quarter was up 34.8% compared to the same quarter last year. During the same period last year, the firm earned $0.16 EPS. On average, analysts expect that Diplomat Pharmacy Inc. will post $0.94 EPS for the current fiscal year.
Several research firms have commented on DPLO. Cowen and Company began coverage on shares of Diplomat Pharmacy in a research report on Thursday, June 23rd. They issued a “market perform” rating and a $37.00 target price for the company. Mizuho upped their target price on shares of Diplomat Pharmacy from $33.00 to $39.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 10th. Zacks Investment Research cut shares of Diplomat Pharmacy from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Leerink Swann upped their target price on shares of Diplomat Pharmacy from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 10th. Finally, Credit Suisse Group AG reaffirmed a “hold” rating and issued a $30.00 price target on shares of Diplomat Pharmacy in a research note on Friday, September 16th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Diplomat Pharmacy presently has an average rating of “Hold” and a consensus price target of $37.50.
In related news, EVP Atheer A. Kaddis sold 20,000 shares of the stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $30.12, for a total transaction of $602,400.00. Following the completion of the sale, the executive vice president now owns 20,000 shares in the company, valued at approximately $602,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Atheer A. Kaddis sold 12,325 shares of the stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $35.76, for a total transaction of $440,742.00. Following the sale, the executive vice president now owns 12,325 shares of the company’s stock, valued at approximately $440,742. The disclosure for this sale can be found here. Corporate insiders own 35.40% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc. (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.